Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of SC-101 in NECTIN4 gene amplification-positive advanced malignant tumors
CTR20252653Phase 2Active
- Sponsor
- Tianjin ConjuStar Biologics Co., Ltd.
- Start
- Jul 2025
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SC-101 in Nonhematologic neoplasms, sponsored by Tianjin ConjuStar Biologics Co., Ltd.. Started Jul 2025; status: active.
02
Drugs
SC-101
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20252653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252653.